2025 GLP-1 Impacts Tell Us About CDMOs In 2026 By Louis Garguilo, Chief Editor, Outsourced Pharma When we began covering the nexus between GLP-1 drugs and CDMO capacity, there were two key questions: Could Novo Nordisk and Eli Lilly (and followers) keep up supply via internal and external manufacturing to meet exponential demand
We then discuss how MuscleTech is using it to power cleaner, more consistent workouts and diet support through a new pre-workout supplement and two weight loss products
With its precise formulation, Desobody targets unwanted fat deposits and gradually eliminates them, resulting in a more contoured and sculpted appearance
Equation to estimate body weight in elderly Mexican women using anthropometric measurements
During sleep, your body repairs cellular damage and replenishes antioxidant stores
TABLE 3 Pharmacokinetic parameters of BPC157 in rats following repeat intramuscular administration of 100 g/kg BPC157 for seven consecutive days (mean SD, n = 6)